Baylis specializes in devices that facilitate access to the left side of the heart, which can be used for procedures like atrial fibrillation ablation, left atrial appendage closure and mitral valve interventions. The deal is expected to close in Q1FY22 and the final amount is subject to closing adjustments.
The acquisition is expected to add meaningful revenue, operating income, and new research and development capabilities across multiple Boston Scientific businesses. Boston Scientific is using the deal to build out its electrophysiology and structural heart businesses, which includes the flagship Watchman LAAC device.
Company Overview – Baylis Medical Company Inc
Company Overview – Boston Scientific Corporation
No of Pages : 51